News

After delay, Kalvista wins FDA OK for drug to treat rare swelling disorder
The company had blamed FDA "resource constraints" for the delay, while a rival drug for hereditary angioedema received an ...
Regeneron Gets Accelerated FDA OK of Lynozyfic for Blood Cancer Treatment
Regeneron Pharmaceuticals has won FDA accelerated approval of its Lynozyfic treatment for certain patients with the blood ...
BioSpace1d
KalVista Wins OK for First On-Demand Hereditary Angioedema Pill
Ekterly’s road to approval was not a smooth one. Last month, the FDA informed KalVista it would not meet its PDUFA date due ...
Wall Street Journal5d
Regeneron Gets Accelerated FDA OK of Lynozyfic for Blood Cancer Treatment - WSJ - The Wall Street Journal
Regeneron on Wednesday said the FDA green light covers Lynozyfic in adults with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a ...
Immunotherapy: The future of cancer treatment and Harvard funding cuts
The hunt for a medical breakthrough has been caught up in the Trump administration's political assault on the university.
Morningstar6d
Regeneron Gets Accelerated FDA OK of Lynozyfic for Blood Cancer Treatment - Morningstar
Regeneron on Wednesday said the FDA green light covers Lynozyfic in adults with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a ...
State PBM regulation hits a SCOTUS roadblock
The Supreme Court declined Monday to consider an appellate court’s 2023 decision overturning portions of an Oklahoma law regulating pharmacy benefit managers.
Congress needs to fix a policy that's blocking rare disease research | Opinion
Senators made the right decision for America's most vulnerable patients ― now, the House must follow suit. The ORPHAN Cures ...
Fallen firefighter's memorial procession goes through Tulsa
TULSA, Okla. — The memorial procession held in honor of a fallen Disney firefighter passed through Tulsa. 31-year-old Billy ...
Baker Mayfield changes his tune over controversial NFL overtime rule that favoured Chiefs and Patrick Mahomes vs. Bucs
In theory, the NFL's overtime coin toss should simply decide which team gets the ball first. But in practice, it's long given ...
pharmaphorum1d
Novartis gets FDA OK for first in its trio of IgAN therapies
Novartis has claimed accelerated approval from the FDA for a second indication for Fabhalta – IgA nephropathy (IgAN) – as it charts a course to blockbuster sales for the drug. The US regulator ...